Evidence map›Paper›PMID 29954850›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2018

Intranasal wnt3a Attenuates Neuronal Apoptosis through Frz1/PIWIL1a/FOXM1 Pathway in MCAO Rats.

Nathanael Matei, Justin Camara, Devin McBride, Richard Camara, Ningbo Xu, Jiping Tang, John H Zhang

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Gen inhibiting the Wnt/CaScientific reports · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Nathanael MateiDepartments of Physiology and Pharmacology.ORCID 0000-0001-6136-1318
Justin CamaraDepartments of Physiology and Pharmacology.ORCID 0000-0002-8831-8333
Devin McBrideDepartments of Physiology and Pharmacology.ORCID 0000-0001-8988-3353
Richard CamaraDepartments of Physiology and Pharmacology.ORCID 0000-0003-0078-117X
Ningbo XuDepartments of Physiology and Pharmacology.ORCID 0000-0001-9055-3597
Jiping TangDepartments of Physiology and Pharmacology.ORCID 0000-0002-2392-9280
John H ZhangDepartments of Physiology and Pharmacology, Johnzhang3910@yahoo.com.ORCID 0000-0002-4319-4285
Czech Academy of Sciences, Institute of Physiology · CZThe University of Texas Health Science Center · USYahoo (United Kingdom) · GB

Funding

Neurovascular Protection for Early Brain Injury after SAHR01NS081740 · NINDS · LOMA LINDA UNIVERSITY · PI ZHANG, JOHN H · 2013 to 2017
$1.6M
NINDS NIH HHS R01 NS081740
6 · The paper itself

Abstract

After ischemic stroke, apoptosis of neurons is a primary factor in determining outcome. Wnt3a is a naturally occurring protein that has been shown to have protective effects in the brain for traumatic brain injury. Although wnt3a has been investigated in the phenomena of neurogenesis, anti-apoptosis, and anti-inflammation, it has never been investigated as a therapy for stroke. We hypothesized that the potential neuroprotective agent wnt3a would reduce infarction and improve behavior following ischemic stroke by attenuating neuronal apoptosis and promoting cell survival through the Frizzled-1/PIWI1a/FOXM1 pathway in middle cerebral artery occlusion (MCAO) rats. A total of 229 Sprague Dawley rats were assigned to male, female, and 9-month-old male MCAO or sham groups followed by reperfusion 2 h after MCAO. Animals assigned to MCAO were either given wnt3a or its control. To explore the downstream signaling of wnt3a, the following interventions were given: Frizzled-1 siRNA, PIWI1a siRNA, and PIWI1a-clustered regularly interspaced short palindromic repeats, along with the appropriate controls. Post-MCAO assessments included neurobehavioral tests, infarct volume, Western blot, and immunohistochemistry. Endogenous levels of wnt3a and Frizzled-1/PIWI1a/FOXM1 were lowered after MCAO. The administration of intranasal wnt3a, 1 h after MCAO, increased PIWIL1a and FOXM1 expression through Frizzled-1, reducing brain infarction and neurological deficits at 24 and 72 h. Frizzled-1 and PIWI1a siRNAs reversed the protective effects of wnt3a after MCAO. Restoration of PIWI1a after knockdown of Frizzled-1 increased FOXM1 survival protein and reduced cleaved caspase-3 levels. In summary, wnt3a decreases neuronal apoptosis and improves neurological deficits through Frizzled-1/PIWI1a/FOXM1 pathway after MCAO in rats. Therefore, wnt3a is a novel intranasal approach to decrease apoptosis after stroke.

Indexed as

Administration, IntranasalAnimalsApoptosisArgonaute ProteinsFemaleForkhead Box Protein M1Frizzled ReceptorsInfarction, Middle Cerebral ArteryMaleNeuronsNeuroprotective AgentsRatsRats, Sprague-DawleyReceptors, NeurotransmitterSignal TransductionWnt3A ProteinArgonaute ProteinsForkhead Box Protein M1Foxm1 protein, ratFrizzled ReceptorsFzd1 protein, ratNeuroprotective AgentsPIWIL1 protein, ratReceptors, NeurotransmitterWnt3A ProteinFOXM1Frizzled-1MCAOPIWI1astrokewnt3a

Identifiers

PMID29954850
PMCPMC6067074
OpenAlexW2810447510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.